Clinicians with obligations to patients and to organizations often assess patients in law enforcement for both therapeutic and nontherapeutic purposes.
AMA J Ethics. 2022;24(2):E111-119. doi:
10.1001/amajethics.2022.111.
After the Indiana HIV outbreak in 2015, Congress partially repealed the ban on needle exchange programs, providing funding for operations but not syringes.
AMA J Ethics. 2016;18(3):252-257. doi:
10.1001/journalofethics.2016.18.3.hlaw1-1603.
This commentary explores legal, ethical, and practical considerations for pharmacists and prescribers working together to address uncertainty in drug prescribing.
AMA J Ethics. 2021;23(6):E471-479. doi:
10.1001/amajethics.2021.471.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"